this protocol describes the isolation of endogenous c-Kit (also known as cD117)-positive (c-Kit + ), cD45-negative (cD45 -) cardiac stem cells (ecscs) from whole adult mouse and rat hearts. the heart is enzymatically digested via retrograde perfusion of the coronary circulation, resulting in rapid and extensive breakdown of the whole heart. next, the tissue is mechanically dissociated further and cell fractions are separated by centrifugation. the c-Kit + cD45 -ecsc population is isolated by magnetic-activated cell sorting technology and purity and cell numbers are assessed by flow cytometry. this process takes ~4 h for mouse ecscs or 4.5 h for rat ecscs. We also describe how to characterize c-Kit + cD45 -ecscs. the c-Kit + cD45 -ecscs exhibit the defining characteristics of stem cells: they are self-renewing, clonogenic and multipotent. this protocol also describes how to differentiate ecscs into three main cardiac lineages: functional, beating cardiomyocytes, smooth muscle, and endothelial cells. these processes take 17-20 d.
IntroDuctIon
Although previously considered to be a terminally differentiated organ, the adult mammalian heart has been shown to have the ability to develop new cardiomyocytes and microvasculature throughout life 1 . It has been further demonstrated that the adult mammalian heart contains a population of resident endogenous stem and progenitor cells, which have the defining characteristics of stem cells: self-renewal, clonogenicity and multipotency 2 . Such cells have been identified by our group and others in a range of different mammalian species, including humans .
Early in this century, the search for the origin of small mononucleated cardiomyocytes undergoing cytokinesis, seen sporadically in normal and pathological adult hearts, including humans 24 , led to the first identification of bona fide resident, endogenous cardiac stem and progenitor cells (eCSCs/eCPCs) that are self-renewing, clonogenic and multipotent, and present in the adult myocardium throughout the organism's life span 2 . Shortly after, several eCSCs in the adult mammalian heart were identified by different membrane markers and transcription factors (which often led to claims of a new stem cell type as new markers were used for identification). Indeed, when referring to eCSCs, there are at least seven resident heart populations so far identified (mainly according to the single antigen used for their primary isolation) in the adult mammalian heart, including the human heart 25 . These are c-Kit + eCSCs (that have been also defined by the markers CD34 -, CD45 -, Sca-1 + , Abcg2 + , CD105 + , CD166 + , GATA4 + , NKX2-5 +/-or low and MEF2C + ) 2,4-9 ; Sca1 + eCSCs (CD34 -, CD45 -, FLK1 -, c-Kit +/-or low , GATA4 + , NKX2-5 +/-or low and MEF2C + ) 10, 11 ; side population cells (CD34 + , CD45 + , Abcg2 + , Sca1 + , c-Kit + , NKX2-5 -and GATA4 -) 12, 13 ; cardiosphere-derived cells (CD105 + , CD34 + , CD45 + , Abcg2 + , Sca1 + and c-Kit low ) [14] [15] [16] ; cardiac-resident colony-forming unit fibroblasts (Sca-1 + , PDGFR-α + , CD31 -, c-Kit low , CD45 -, FLK1 -, CD44 + , CD90 + , CD29 + and CD105 + ) 17 ; cardiac mesangioblasts (CD31 + , CD34 + , CD44 + , CD45 -, Sca1 + and c-Kit + ) 19 ; and Isl-1 + CPCs (CD31 -, Sca1 -, c-Kit -, GATA4 + and NKX2-5 + ) 20, 21 . The phenotypes and sources of these cell populations are summarized in Table 1 .
The description of these various eCSC populations led to the paradoxical situation whereby the heart, previously described as a nonrenewing organ, became the organ with the highest number of distinct types of resident stem and progenitor cells. However, aside from the Isl-1 + CPCs, which are the direct progeny of a defined embryonic CPC population present in only very small numbers in the adult heart 26 , and the epicardial stem cells (also called cardiac-resident colony-forming unit-fibroblasts, presumably derived from the pro-epicardial organ 17 ), it is evident just from the substantial overlap of the main and secondary markers used for their characterization that the different eCSC/CPC populations are closely related. Therefore, it is not surprising that a consensus is developing that many, if not all, different putative adult eCSCs reported so far probably represent different developmental and/or physiological stages of a unique resident stemprogenitor cell type with multipotent regenerative capacity yet to be completely defined 27 . Clearly, genetic tracking in genetically modified mice, if properly designed, would be an invaluable tool in trying to establish the connection among the different eCSC/CPC populations as well as their real contributions to heart development, adult myocardial homeostasis and disease.
The c-Kit + eCSCs are characterized by expression of c-Kit (CD117), the receptor for stem cell factor. Although in the myocardium c-Kit is also expressed by cardiac mast cells, which in contrast to eCSCs are also CD45 + and tryptase (Tryp)-positive, removal of the CD45 + cell lineage removes this mast cell population 6 . The abundance, distribution and intrinsic regenerative capacity of c-Kit + eCSCs in adult cardiac tissue have been recently clarified 4 , although their developmental origin has not yet been lineage traced (for review, see refs. 28, 29) . It is desirable when isolating eCSCs from adult tissue to obtain a cell population of the highest possible uniformity in terms of lineage potential, with the cells retaining the ability to develop into all four cell lineages required to regenerate the myocardium (cardiomyocyte, vascular (endothelial and smooth muscle) and fibroblast). It has been repeatedly demonstrated 2, [4] [5] [6] that the c-Kit + eCSC population is sufficiently primitive to retain this quadri-lineage potential, indicating that these are uncommitted cells, i.e., bona fide stem and progenitor cells.
Here we present effective and highly reproducible protocols for the isolation of c-Kit + CD45 -Tryp -eCSCs from the adult whole mouse (C57/BL6J) and rat (Wistar) heart, the most commonly used small animal models for experimental cardiovascular research. These protocols were originally developed during the first identification of eCSCs 2 . The protocols described here are broadly similar for mouse and rat hearts and result in the isolation of similar type and number of cells; however, there are several procedural differences. The key factor in both is the retrograde coronary perfusion step, a process initially described by Silver et al. 30 , in which the coronary arteries are used as a route for buffer and digestive enzyme to perfuse through the myocardium. This procedure first removes peripheral blood cells and endothelial cells present in the vascular tree and subsequently induces prompt digestion of the tissue, thus making it possible to isolate separate fractions of the main cardiac cell types (i.e., cardiomyocytes, smooth muscle cells, endothelial cells, cardiac fibroblasts and eCSCs). Compared with other methods, retrograde coronary perfusion and digestion of the whole heart allows the collection of the highest number of eCSCs and it also makes it possible to simultaneously collect rod-shaped cardiomyocytes. In addition, we describe how to characterize the isolated c-Kit + CD45 -Tryp -eCSCs and how to induce and characterize their differentiated progeny.
Advantages of the protocol
The main advantages of retrograde perfusion of the coronary tree with the digestive enzymes are the increased yield and high purity of c-Kit + CD45 -Tryp -eCSCs (described as eCSCs) that are extracted. The isolated eCSCs can be immediately studied further, cryogenically stored, characterized, cloned or expanded in vitro. A major difficulty in working with eCSCs from adult myocardium is their scarcity and therefore many methods for their isolation require an in vitro expansion step. Although this is effective, depending on the questions addressed, the expansion of the eCSCs in the culture environment may represent a confounding variable. The methods described here allow a sizeable population of eCSCs to be obtained without the need to include an in vitro expansion step.
Experimental design
This protocol describes the isolation of small cells (<40 µm in diameter) from the mouse (Step 1A) or rat (Step 1B) heart, with the subsequent removal of CD45 + hematopoietic lineage cells, which remove the blood cell lineage precursors and the mast cells (Tryp + ), followed by the selection of the cell population positive for c-Kit. The differences between the two protocols are summarized in Table 2 . When flow cytometric analysis of the selected eCSC population is planned, it is necessary to collect an aliquot of unsorted cardiac small cells for isotype control for the mouse, and the same process is advisable for the rat. By using the rat protocol it is also possible to isolate intact, contracting, calcium-resistant, rod-shaped cardiomyocytes, should this be required. The mouse rod-shaped cardiomyocytes are considerably more delicate than rat cardiomyocytes and many will be killed by a leaky membrane that allows an influx of extracellular Ca 2+ .
It is crucial when using the retrograde perfusion method described here that the time from the death of the animal to successful placement of the heart on the perfusion system be minimized. Blood clotting and subsequent occlusion of the vessels must be prevented to allow adequate retrograde tissue perfusion. Inefficient digestion of the tissue by the perfused enzyme solution reduces the quantity and quality of cells recovered. In addition, the number of circulatory hematopoietic lineage cells contaminating the pool of small cells is increased. Intraperitoneal (i.p) injection of heparin to the animal before euthanasia reduces blood clotting and improves perfusion, as does rapid cannulation and prompt hanging of the heart on the perfusion system.
Given the relatively small number of c-Kit + CD45 -eCSCs that can be isolated from a single heart, we recommend that eCSCs be collected from no fewer than 3-6 C57/BL6J mice or two Wistar rats at a time. This circumvents the fact that if eCSCs are initially seeded at a very low cell density, early cell growth is very slow.
Once the eCSCs are in culture, medium must be replenished every 2-3 d. Growth can be further enhanced by the use of conditioned medium, which enables a quasi-logarithmic growth rate to be achieved. Passaging of cells when they reach ~70% confluency prevents overgrowth and cell-to-cell contact, which can lead to cell growth inhibition and/or differentiation. A limitation of the protocol is that we use custom-made specialized equipment for the perfusion and digestion of the ex vivo whole heart. However, a commercially available version comparable to our system is available from AD Instruments (cat. no. PL3508B1-V for mouse, B3-V or B4-V for rat), which should allow our system to be reproduced by researchers without access to custom-made apparatus. Although we have not tested side-by-side the efficacy of the commercial apparatus compared with our equipment, if the basic principles of our method are followed they should prove to be effective.
Once the c-Kit + CD45 -eCSCs have been isolated, flow cytometry can be used to confirm expression of various stem cell surface markers. The cells can also be grown in culture. This protocol also describes how to characterize the cells for the stem cell properties of clonogenicity, self-renewal and multipotency (Steps 2A and 2B); how to differentiate either mouse or rat c-Kit + CD45 -eCSCs into functional, beating cardiomyocytes in vitro (Step 2C); and how to fix and stain cells by immunocytochemistry (Steps 2D-F). • REAGENT SETUP Incubation medium for sorting mouse or rat cells PBS without calcium or magnesium containing BSA (5 mg/ml), EDTA (2 mM), penicillin-streptomycin (1% (vol/vol)), Fungizone (0.1% (vol/vol)) and gentamicin (0.1% (vol/vol)). Prepare 50 ml of incubation medium, sterilize it through a 0.22-µm-pore filter into a sterile container and store it at 4 °C for up to 3 weeks. Basic buffer for isolating mouse cells Basic buffer comprises MEM (Joklik modification) containing sodium bicarbonate (2 grams per liter), HEPES (0.7 mg/ml), taurine (1.25 mg/ml) and glutamine (0.3 mg/ml). Prepare 1,000 ml of basic buffer (pH 7.3) and sterilize it through a 0.22-µm-pore filter into a sterile container. This may be prepared up to 3 d before tissue collection if kept sterile at 4 °C. Collagenase buffer for isolating mouse cells Collagenase buffer is collagenase powder at a final concentration of 250 U/ml in basic buffer. Prepare 200 ml of collagenase solution and filter-sterilize it as for basic buffer; this volume is sufficient to perfuse 3-6 hearts if the collagenase is collected after perfusion and recycled.  crItIcal The buffer must be prepared shortly before tissue collection and the solution must be kept chilled before use in order to minimize enzyme degradation. BSA incubation buffer for isolating mouse cells This buffer is 5 mg/ml BSA in basic buffer. Prepare 200 ml of BSA incubation buffer and filter-sterilize it as for basic buffer; this volume is sufficient to perfuse three hearts, or six if the solution is collected and recycled. This solution can be prepared the day before tissue collection and stored at 4 °C before use. Mouse eCSC growth medium First make up two solutions (as established in ref. 4) . Solution 1 comprises DMEM-F12-Ham's containing insulin-transferrin-selenium (1% (vol/vol)), penicillin-streptomycin (1% (vol/vol)), Fungizone (0.1% (vol/vol)) and gentamicin (0.1% (vol/vol)). Solution 2 comprises Neurobasal medium supplemented with 37 mg of l-glutamine (500 ml), B27 supplement (2% (vol/vol)) and N2 supplement (1% (vol/vol)). To prepare the growth medium, mix the solutions in the following ratio: 45% solution 1, 45% solution 2 and 10% embryonic stem cell-qualified FBS. Make up 200 ml of growth medium, adding epidermal growth factor (20 ng/ml), basal fibroblast growth factor (10 ng/ml) and leukemic inhibitory factor (10 ng/ml); sterilize it through a 0.22-µm-pore filter into a sterile container and store it at 4 °C for up to 3 weeks.
Krebs-Henseleit (K-H) buffer for isolating rat cells
The buffer comprises the following: sodium chloride at a final concentration of 6.896 grams per liter; potassium chloride at a final concentration of 0.35 grams per liter; magnesium sulfate at a final concentration of 0.144 grams per liter; potassium phosphate at a final concentration of 0.1635 grams per liter; sodium bicarbonate at a final concentration of 2.1 grams per liter; and dextrose at a final concentration of 2.16 grams per liter. Prepare 1,000 ml of buffer, adding 50 ml of concentrated stock solutions of sodium chloride, potassium chloride, magnesium sulfate, potassium phosphate and sodium bicarbonate to ddH 2 O to a total volume of 1,000 ml, followed by addition of 2.16 g of dextrose; filter-sterilize it through a 0.22-µm-pore filter into a sterile container. This may be prepared and stored at 4 °C for up to 1 week. Wash medium for isolating rat cells The wash medium is 25 ml of K-H buffer, 25 ml of DMEM and 250 µl of penicillin-streptomycin. Prepare wash medium, sterilize it through a 0.22-µm-pore filter into a sterile container and store it at 4 °C for up to 1 week. Collagenase and hyaluronidase solution for isolating rat cells The solution comprises 150 ml of K-H buffer containing collagenase, type II (final concentration of 128 U/ml) and hyaluronidase, type II (final concentration of 200 U/ml). Prepare 150 ml of collagenase and hyaluronidase solution and sterilize it through a 0.22-µm-pore filter into a sterile container. The volume is sufficient for perfusion of three rat hearts, but it has to be collected and reused over this time.  crItIcal This solution must be prepared shortly before tissue collection and the solution kept chilled before use in order to minimize enzyme degradation.
• • • •
Rat eCSC growth medium First make up three solutions (as established in refs. 4, 31, 32) . Solution 1 comprises DMEM-F12-Ham's containing insulin-transferrin-selenium (1% (vol/vol)), epidermal growth factor (final medium concentration: 20 ng/ml), basal fibroblast growth factor (final medium concentration: 10 ng/ml) and leukemia inhibitory factor (final medium concentration: 10 ng/ml). Solution 2 comprises Neurobasal medium supplemented with 37 mg of l-glutamine (500 ml), B27 supplement (2% (vol/vol)) and N2 supplement (1% (vol/vol)). Make up the growth medium by mixing the solutions in the following ratios: 45% solution 1, 45% solution 2 and 10% embryonic stem cell-qualified FBS. Prepare 200 ml of growth medium, adding penicillin-streptomycin (1% (vol/vol)), Fungizone (0.1% (vol/vol)) and gentamicin (0.1% (vol/vol)); sterilize it through a 0.22-µm-pore filter into a sterile container and store it at 4 °C for up to 3 weeks. Incubation medium for Cytospin or flow cytometry The medium comprises PBS (without calcium or magnesium) containing BSA (5 mg/ml), EDTA (2 mM), penicillin-streptomycin (1% (vol/vol)), Fungizone (0.1% (vol/vol)) and gentamicin (0.1% (vol/vol)). Prepare 50 ml of incubation medium, sterilize it through a 0.22-µm-pore filter into a sterile container and store it at 4 °C for to 3 weeks. Prepare 200 ml of differentiation medium, sterilize it through a 0.22-µm-pore filter into a sterile container and keep it light-shielded at 4 °C for up to 3 weeks. EQUIPMENT SETUP Perfusion system for mouse and rat heart perfusion Our system consists of flexible tubing run through a fluid pump that draws up fluid (e.g., basic buffer) and propels it through our custom-made glass tubing system for fluid heating, in which the fluid is heated to 37 °C by passing through coils inside chambers filled with an external water supply warmed to 37 °C (this external water temperature is regulated by the water bath). The warmed fluid then drips out via the tubing, with the terminal tube of a diameter that allows firm attachment of the cannulae. See Figure 1 for a diagram of our system. Alternatively, AD Instruments sells a perfusion system (cat. no. PL3508B1-V for mice and B3-V or B4-V for rats). (ii) Inject 1,000 IU/kg of heparin sulfate i.p. into a 6-week-old C57/BL6J mouse, and after ~10 min euthanize the animal (we use an overdose of sodium pentobarbitone). Sterilize the anterior surface and dissect as follows: open the skin on the abdomen with a midline incision and retract the fur and skin; open the abdominal cavity and make lateral incisions on the inferior edge of the ribcage; make vertical cuts along the lateral border of the ribcage and then transversely across the diaphragm to expose the heart. ! cautIon All experiments on mice must be performed in accordance with relevant guidelines and regulations.  crItIcal step If intending to isolate RNA directly from isolated eCSCs, it is advisable to omit heparin administration: in this instance rapid cannulation is even more vital.  crItIcal step This and the following two steps must be carried out rapidly: depending on the number of operators and facilities available, it may be necessary to euthanize mice one at a time. If the time elapsed from euthanasia to perfusion is longer than 10 min, the yield and quality of the isolated eCSCs will be severely negatively affected. (iii) Remove the ribcage flap at the superior end and discard it; remove the thymus with forceps to expose the arch of the aorta; thread an 8-cm length of 5/0 suture behind the ascending aorta with fine forceps; hold the innominate artery in place with fine forceps and cut partway through the aorta immediately distal to the origin of the innominate with Vannas scissors, thereby producing an opening over the ascending aorta; insert a fine-bore cannula (19 gauge) into the opening and advance gently into the ascending aorta, being sure to stop before passing through the aortic valve and entering the ventricular cavity; tie the cannula in place with the 5/0 suture; grasp the aorta over the cannula tie with forceps and fully dissect the heart out from the thoracic cavity ( Fig. 2a-f ).
? troublesHootInG (iv) Place the cannula into the aperture of the retrograde perfusion system (Fig. 2g) with the pump running at 10.2 ml/min, equating to 3.4 ml/min/cannula, and perfuse the heart with basic buffer for 5 min or until all blood has been removed. If necessary, pierce the apex with a 25-gauge needle to allow pooled blood to be removed. Also check for leaks between the cannula and the aortic root. Re-do or tighten the suture connection if needed.
? troublesHootInG (v) Once the blood is removed, perfuse the heart with collagenase solution for 10-12 min to digest the tissue. The heart should enlarge slightly, and the tissue will become pale and flaccid if perfusion is successful (Fig. 2h) . ? troublesHootInG (vi) Next, perfuse the heart with BSA solution for 5 min to stop the collagenase reaction and prevent overdigestion.
Depending on the perfusion apparatus, it should be possible to perfuse three or four hearts simultaneously. (vii) Once all hearts have been fully perfused, collect them and transfer them to a 25-ml conical flask (three hearts per flask, 5-10 ml of BSA solution per flask); chop them into ~1-2-mm pieces with fine sterile scissors.
? troublesHootInG (viii) Run the suspension up and down through a transfer pipette ten times to further break up the tissue fragments.
? troublesHootInG (ix) Transfer the suspension into a 15-ml centrifuge tube and centrifuge it at 300g, brake 3, for 1 min at room temperature (20-22 °C) to separate the suspension into myocyte and small cell fractions. If the recovery and study of the cardiomyocyte fraction is desired, the cells within the pellet can be retrieved at this stage as previously described 4 . (x) Retain the supernatant (containing the small cell fraction) and pass it through a 40-µm cell strainer into a 50-ml centrifuge tube. Next, add BSA solution to give a total volume of 30 ml per tube. (xi) Centrifuge the tube at 330g, brake 7, for 7 min at room temperature to pellet small cell fraction. Discard the supernatant and resuspend the pellet in 1 ml of incubation medium. Count an aliquot of the cells with a hemocytometer before proceeding to the next steps (cell selection). (Fig. 3a,b) . Alternatively, proceed directly to the next step to purify the c-Kit + CD45 -eCSCs via magnetic cell sorting (Step 1A(xiii-xv)). If you intend to carry out flow cytometric analysis of the selected eCSC population, retain an aliquot of unsorted cardiac small cells for the isotype control (supplementary Fig. 1 ). (xiii) Label the CD45 + cells using the Miltenyi Biotec anti-mouse CD45 MicroBead kit, according to the manufacturer's instructions. In brief, first resuspend the cell fraction in incubation medium with the MicroBeads (volume of 20 µl MicroBeads per 10 7 cells; cell number as ascertained in step 1A(xiv)) and incubate the suspension for 15 min at 4 °C. Wash it in incubation medium before centrifugation and resuspension in incubation medium. Finally, run the cell suspension through a MS magnetic sorting column placed in an OctoMACS magnet attached to its stand (Miltenyi Biotec) with a 30-µm pre-separation filter (Miltenyi Biotec) fitted above the column. Run the suspension through the system dropwise, followed by three washes with 500 µl of incubation medium to rinse through all the unbound cells. Proceed to the next step to further purify the unlabeled cell fraction (CD45 -fraction). Retain the positively labeled cells for later flow cytometric analysis.
? troublesHootInG (xiv) Use the CD45 -fraction (from Step 1A(xiii)) with the STEMCELL Technologies's EasySep anti-mouse CD117 kit to label the CD117 + (c-Kit + ) fraction, according to the manufacturer's instructions. In brief, first label the CD45 -cell fraction with an anti-c-Kit antibody conjugated to PE for 15 min, followed by an anti-PE/anti-dextran secondary antibody complex for 15 min, and finally with magnetic dextran-iron nanoparticles to tag the secondary antibody for 10 min (all incubations are at room temperature). After these incubations, rinse the cells with 5 ml of incubation medium and place them inside the EasySep magnet for 5 min at room temperature. Empty the tube while it is still within the magnet, thus retaining all labeled cells. Rinse the cells and empty the magnet a total of five times. Finally, remove the tube from the magnet. (b) Isolation of c-Kit + ecscs from the rat heart • tIMInG ~4.5 h ? troublesHootInG (i) Rinse the perfusion system with 70% (vol/vol) ethanol for 10 min to sterilize, and then re-rinse with ddH 2 O for 10 min to remove all traces of ethanol before use. Commence running the K-H buffer through the system. (ii) Inject 1,000 IU/kg heparin sulfate i.p. into an 8-week-old Wistar rat, then after ~10 min euthanize the rat and dissect it as follows: open the skin on the abdomen with a midline incision and retract the fur and skin; open the abdominal cavity and make lateral incisions on the inferior edge of the ribcage; make vertical cuts along the lateral border of the ribcage and then transversely across the diaphragm to expose the heart. ! cautIon All experiments on rats must be performed in accordance with relevant guidelines and regulations.  crItIcal step If you are intending to isolate RNA directly from isolated eCSCs, it is advisable to omit heparin administration: in this instance, rapid cannulation is even more vital.  crItIcal step This and the following two steps must be carried out rapidly: similarly to mice, it may be necessary to euthanize rats one at a time. If the time elapsed from euthanasia to perfusion is longer than 10 min, the yield and quality of the isolated eCSCs will be severely negatively affected. (iii) Remove the ribcage flap at the superior end and discard it; remove the thymus with forceps to expose the arch of the aorta and fully dissect out the heart, ensuring that at least 3 mm of the aortic stump is removed along with the heart. ? troublesHootInG (iv) Lift the heart using forceps placed on walls of the aortic stump, and then lift onto cannula, with aortic walls around the cannula end (do not enter the ventricular cavity). Secure and tie the cannula in place with 4/0 suture thread (Fig. 6a-c) and perfuse the heart (pump running at 20.4 r.p.m.: equating to 6.8 ml/min/cannula) with K-H buffer for 5 min or until all blood has been removed. If necessary, pierce the apex with a 21-gauge needle to allow the pooled blood to be removed. As for the mouse, check for leaks between the cannula and the aortic root. Re-do or tighten the suture connection if needed. ? troublesHootInG (v) While K-H buffer rinsing is ongoing, very carefully place forceps inside the heart chambers via the openings of the great vessels and open and close them slightly to dislodge pooled blood and aid perfusion. (vi) Once all the blood is removed, perfuse the heart with collagenase/hyaluronidase solution for 15 min to digest the tissue. The heart should enlarge slightly and tissue will become pale and flaccid if perfusion is successful. As with the mouse, it should be possible, depending on the perfusion apparatus, to perfuse three hearts simultaneously (Fig. 6d) . (vii) Remove each heart from the cannula and place it a sterile, lidded container with 15 ml of collagenase/hyaluronidase solution; cut into pieces (~5 mm in size).
? troublesHootInG (viii) Add 15 µl of 1 M calcium chloride (only if you are interested in collecting the cardiomyocytes), trypsin (to a final concentration of 20 µg/ml) and DNase (to a final concentration of 20 µg/ml) to the 15-ml collagenase/hyaluronidase tissue suspension. ? troublesHootInG (ix) Place the tissue suspension in a shaking water bath at 150 r.p.m. at 37 °C for 40 min to dissociate the tissue.
? troublesHootInG (x) Pipette the suspension up and down through a 25-ml pipette ten times to fully break up tissue fragments, and then run the suspension through a cell strainer (100-µm filter pore size) into a 50-ml centrifuge tube. Rinse the suspension container with 40 ml of wash medium and add this (through the cell strainer) to the cell suspension. Divide equally into a second 50-ml centrifuge tube.
? troublesHootInG (xi) Centrifuge both tubes at 50g, brake 3, for 3 min at room temperature, collecting the supernatants (containing the small cell fraction), and run them through a cell strainer (40-µm filter pore size) into two new centrifuge tubes. At this step, the cardiomyocyte pellet can be resuspended and run through a BSA gradient to separate viable rod-shaped cardiomyocytes if required, as previously described 32 . (xii) Centrifuge the tubes at 400g, brake 7, for 7 min at room temperature and discard the supernatants, combining both small cell pellets in incubation medium. In particular, we examine the expression of CD45 and c-Kit (Fig. 7a,b) . Alternatively, proceed directly to the next step to purify the c-Kit + CD45 -eCSCs by magnetic cell sorting (Step 1B(xv-xviii)). If you intend to carry out flow cytometric analysis of the selected eCSC population, retain an aliquot of unsorted cardiac small cells for the isotype control (supplementary Fig. 1c ). (xv) Incubate the cardiac small cells (from Step1B(xiv)) with anti-rat CD45 antibody (Santa Cruz), applied at a concentration of 1 µg per million cells in incubation medium (to a total volume of 1 ml) for 15 min at 4 °C and centrifuge at 300g, brake 7, for 7 min at 4 °C, discarding the supernatant. At this point, mast cells can be identified by immunostaining for tryptase (Fig. 7c) , if desired. ? troublesHootInG (xvi) Incubate the cells with Miltenyi Biotec rat anti-mouse IgG MicroBeads, according to the manufacturer's instructions.
In brief, label the resuspended cell fraction in incubation medium with the MicroBeads for 15 min at 4 °C, wash it in incubation medium and then pellet by centrifugation and resuspend it in incubation medium. Run the cell suspension dropwise through a magnetic sorting MS column placed in an OctoMACS magnet attached to its stand (Miltenyi Biotec), with a 30-µm pre-separation filter (Miltenyi Biotec) fitted above the column. Wash the column three times with 500 µl of incubation medium to rinse through all unbound cells. Collect the unlabeled cell fraction and retain the positively labeled cells for later flow cytometric analysis.
? troublesHootInG (xvii) Incubate the unlabeled cell fraction from Step 1B(xvi) (CD45 -cells) with anti-c-Kit antibody (Santa Cruz) for 30 min in incubation medium (to a total volume of 1 ml) at 4 °C; centrifuge at 300g, brake 7, for 7 min at 4 °C, discarding the supernatant. ? troublesHootInG (xix) Count the c-Kit + CD45 -cell fraction with a hemocytometer. We usually obtain ~150,000 c-Kit + CD45 -cells from each rat heart (~170 eCSCs per mg of tissue). Use trypan blue exclusion to ensure that the cell viability is >95%. At this stage, flow cytometric analysis of the cell population purity can be carried out (Figs. 8 and 9 ). (xx) If in vitro culture of the cells is required, resuspend the cells in rat eCSC growth medium and plate them on plates precoated with 1.5% (wt/vol) gelatin (see table 4 for cell plating density). If cell culture is not required proceed directly to characterization (Step 2).
? troublesHootInG (xxi) Allow cells to multiply, feeding after 24 h in culture and then every 2-3 d, and passaging when cells reach ~70% confluence. As for mouse eCSCs, cell growth may be assisted by using medium previously conditioned by eCSCs in vitro, to up to 50% of the total medium volume (mixed with fresh medium). Ensure that a large enough hole is cut in the aorta
Mouse aorta tears when the cannula is inserted
Ensure that the aorta cut is vertical (a diagonal cut increases the risk of tearing the innominate artery during cannula insertion)
Heart falls off the perfusion system
Ensure that the aorta is well tied onto the cannula; ensure that the cannula is sufficiently advanced into the aorta (continued) 
• tIMInG
Step 1A, isolation of c-Kit + eCSCs from mouse heart: ~4 h
Step 1A(i): ~25 min
Step 1A(ii-vi): ~1 h (assuming three hearts are processed)
Step 1A(vii-xi): ~25 min
Step 1A(xii-xvii): ~2 h
Step 1B, isolation of c-Kit + eCSCs from rat heart: ~4.5 h
Step 1B(i): ~25 min
Step 1B(ii-vii): ~1 h (assuming three hearts are processed; ~20 min for one heart)
Step 1B(viii-xiv): ~70 min
Step 1B(xv-xxi): ~2 h
Step 2A, clonogenicity assay: ~9 d
Step 2B, generation of CardioStem spheres: ~6 d
Step 2C, cardiomyogenic differentiation of eCSCs in vitro: ~20 d (3 d oxytocin pre-treatment; ~3 d to grow CardioStem spheres; and 14 d of differentiation in defined stage-specific medium)
Step 2D, cytospin procedure: ~35 min
Step 2E, chamber slide preparation procedure: ~7 d (to assay multipotency) or ~20 d (for cardiomyogenic differentiation)
Step 2F, immunocytochemistry procedure: ~5 h to complete working around an overnight incubation for the primary antibody
Step 2G, real-time qPCR analysis: ~6 h antIcIpateD results
Isolating c-Kit + ecscs from the mouse heart
Flow cytometric analysis of the c-Kit and CD45 expression of cardiac small cells from the adult mouse heart demonstrates that in the unsorted cardiac small cell population ~10% of small cells present in the adult mouse heart are c-Kit + CD45 + (Fig. 3a,b) and Tryp + . These cells are cardiac mast cells 6, 33 . Among the cardiac small cell population, typically, ~3% are c-Kit + CD45 -Tryp -eCSCs (Fig. 3b) .
To confirm the efficacy of the magnetic cell sorting system, we incubated sorted cells from Step 1A(xii) with fluorochrome-conjugated antibodies and analyzed them by flow cytometry. The removal of CD45 + cells is completely effective, with the CD45 + signal (labeled with fluorescein isothiocyanate, FITC) being removed entirely by negative selection of this cell population with magnetic activated cell sorting (Fig. 4a-c) . Similarly, a strongly enriched population of cells for c-Kit is provided by magnetic selection for this population (Fig. 5a-c) . By dual staining, ~93% of cells are c-Kit + CD45 -after magnetic selection for these markers (Fig. 5d,e) . As the c-Kit + CD45 -eCSCs have been sorted using a PE-conjugated antibody, c-Kit-unsorted cardiac small cells are used as a PE isotype control, because these cells have a comparable forward scatter/side scatter (FSC/SSC) distribution to that of the eCSC population (supplementary Fig. 1 ). Flow cytometric analysis of c-Kit and CD45 expression in cardiac small cells obtained at
Step 1B(xiv) from the adult rat heart demonstrates that in the unsorted cardiac small cell population, ~14% of the small cells present in the adult heart are c-Kit + CD45 + (Fig. 7a,b) and Tryp + . These cells are cardiac mast cells (Fig. 7c) . Among the cardiac small cell population, typically ~4% are c-Kit + CD45 -Tryp -eCSCs (Fig. 7b) .
To confirm the efficacy of the magnetic cell sorting system, we incubated sorted cells with fluorochrome-conjugated antibodies and analyzed them by flow cytometry. As we saw for the mouse, the removal of CD45 + cells is effective with the CD45 + signal (labeled with FITC) being 83% in the positive selection and 3% in the negative selection (Fig. 8a-c) . Similarly, a strongly enriched population of cells for c-Kit is provided by magnetic selection for this population (Fig. 9a-c) . We note that the c-Kit + eCSC population expresses varying levels of c-Kit (Fig. 9c) , which may reflect different levels of potency or the clipping of a fraction of c-Kit by the proteolytic digestion step. The cause of this heterogeneity of detectable c-Kit remains to be determined. By dual staining, ~86% of cells are c-Kit + CD45 -Tryp -after magnetic selection for these markers (Fig. 9d,e) , with the complete absence of the mast cell marker tryptase (Fig. 9f) .
characterization of ecscs
Flow cytometric analysis of freshly isolated c-Kit + CD45 -eCSCs for a panel of surface markers (Fig. 10) reveals a phenotype that is ~50% positive for Sca-1 and CD90 (Fig. 10a,b) ; ~60% positive for CD105 and CD140a (PDGFr-α) (Fig. 10c,d) ; ~65% positive for CD166 (Fig. 10e) ; and negative for CD31 and CD34 (Fig. 10f,g) .
The c-Kit + CD45 -eCSC populations derived from both mouse and rat adult hearts can be grown in culture beyond the population doubling limit of somatic cells (i.e., >40 passages over a period of months). Clonal populations of mouse and rat c-Kit + CD45 -eCSCs have a population doubling time of ~15 h (Fig. 11a) , and they can be characterized by flow cytometry for appropriate eCSC surface marker expression (Fig. 11b) .
The c-Kit + CD45 -eCSCs from the mouse and rat heart are self-renewing, maintaining stemness transcript expression over 30 consecutive culture passages (Fig. 11c) . Mouse and rat c-Kit + CD45 -eCSCs at passage 4 have the ability to generate single cell-derived clonal colonies at a rate of ~30% (Fig. 11d) , and also to generate CardioStem spheres when grown in suspension (Fig. 11e) .
Depending on the cell types to be immunostained, either Cytospin preparations (for eCSCs) or chamber slides (for differentiated cells) are used. These methods allow successful immunocytochemical characterization of c-Kit + CD45 -eCSCs (Fig. 12a) and c-Kit + CD45 -eCSCs that have been differentiated into the three main cardiac lineages (Figs. 12b-d  and 13) . The generation of the three lineages is achieved by generating CardioStem spheres, which are then plated in laminin-coated chamber slides. CardioStem spheres are similar to neurospheres 34 and cardiospheres 14 , with the difference being that they are constituted of eCSCs instead of mixed small cells from the originating tissue. Once attached, cells from the CardioStem spheres spontaneously differentiate into cells expressing markers of all three cardiac lineages, namely, cardiomyocytes (α-sarcomeric actin: Fig. 12b) , smooth muscle cells (SMA: Fig. 12c ) and endothelial (von Willebrand factor, vWF: Fig. 12d ) cells 2 .
This protocol can also be used to specify rat c-Kit + CD45 -eCSCs into functional, contracting cardiomyocytes in vitro. Oxytocin and specific growth factors governing embryonic cardiogenesis, given in a stage/sequence-specific manner ( Fig. 13a) , produced contractile cardiomyocytes derived from cloned c-Kit + CD45 -eCSCs, as previously shown 35 . This CardioStem sphere-beating assay is similar to the protocol used to assess cardiomyocyte differentiation in embryoid bodies 36 . Cloned c-Kit + CD45 -eCSCs are treated with 100 nM oxytocin for 72 h before transfer to bacteriological dishes for the generation of CardioStem spheres (Fig. 13a) . Spheres grown in suspension are picked and plated in laminin-coated chamber slides or dishes. Through trial and error, we identified and demonstrated that supplementation of BMP-2, BMP-4, TGF-β1 and Dkk-1 for 4 d increased the number of cardiac troponin I-expressing cells to ~40% (Fig. 13b) . However, with the removal of TGF-β1, BMP2 and BMP4 on day 4, and supplementation of the medium with Dkk-1 for the remaining 10 d, the cardiomyocyte differentiation increased to ~70% cTnI + cells (Fig. 13a,b) . The cardiomyocyte cells exhibit abundant, well-organized sarcomere structures (Fig. 13c) and functional synchronized rhythmic beating (supplementary Video 1), which is stable and maintained for the duration of the culture. These cardiomyocytes behave similarly to a syncytium connected through Cnx43-containing gap junctions (Fig. 13c) . A similar beating phenotype is exhibited by isolated cells when the sphere is disaggregated and cells individually plated (supplementary Video 2). Real-time qPCR of differentiated CardioStem spheres at 14 d of culture in the cardiomyogenic cocktail showed a progressive decrease in transcripts for stemness and concomitant upregulation of cardiomyocyte-specific transcription factors and genes coding for sarcomeric proteins (Fig. 13d) . This procedure was carried out using the primers and protocol previously published by our group 4 . The identification, isolation and propagation of a population of tissue-specific stem cells resident in the adult heart open strong possibilities for a potential therapeutic option. Early trials of cardiac repair and regeneration via transplantation of bone marrow-derived stem/progenitor cells have given mixed and modest results (for review, see ref. 37 ), indicating that a better understanding of the relevant cell biology is required to provide a consistently effective therapeutic option for stem cell-based regenerative treatments in the heart. The presence of resident eCSCs in the adult heart, including the human heart, has been determined by several groups 2, 4, 6, [8] [9] [10] 12, 14, 17, [38] [39] [40] [41] [42] . These cells can be isolated and propagated in vitro to produce large numbers of cells without reaching growth arrest or without a change in cell characteristics. The cells are multipotent in vitro and in vivo 2, 6, 14 . Therefore, these cells could be a source of a potential regenerative agent. The recent results of the SCIPIO (cardiac stem cell infusion in patients with ischemic cardiomyopathy) and CADUCEUS (cardiosphere-derived autologous stem cells to reverse ventricular dysfunction) trials 43, 44 provide further evidence of the potential therapeutic capabilities of these cells, demonstrating a therapeutic action of autologous eCSC infusion in patients after myocardial infarction. Other possible uses for purified eCSCs include developing drug test assays and obtaining patient-specific models of disease via CPCs derived from eCSCs in the manner achieved with human induced pluripotent stem cells 45 . Thus, this protocol enables the effective isolation and characterization of the c-Kit + CD45 -eCSC population in adult mouse and rat hearts.
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